Ann: ResAppDx-EU in Use at COVID-19 Respiratory Clinic, page-101

Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #

First 101 Last

Share
Profile

Follow
AlCp

27,807 Posts.

1793

11/05/20

15:10

Post #: 44553370
Share

Originally posted by Mr.Red ↑

IMO the market is still not convinced on the potential revenue stream... this is what needs confirmation moving forward.. hence why the SP keeps consolidating around this level..

RAP are lining up all their ducks in a row... the recent placement Im still uneasy about, but regardless the re-rate is coming... the recent placement may be holding us back a little as they may wish to cash in for work rendered..

One thing I am confident about, the day the announcement comes out that we have launched to the general public, along with being endorsed from the use in the medical world with government backing, then a serious spike in the SP will be witnessed...

I think the market has valued this to around 20cents SP, give or take... S/Price is all based on speculation of potential... however once the speculation turns into clear confirmed revenue figures, we RAP holders will have our day in the sun..

We are cashed up... WE are now in the spot light... timing is everything... Time is now...

I would presume the media will be hot on today's news, tomorrow will be a stronger day once this news circulates.. can only hope we move into the mid 20's by the end of the week...

Personally think we holders are about to finally have some rewards come our way..

had a look at the chart today... pennant/flag has been set up... looks to break out... volumes IMO are still low... again some stronger announcements projecting potential revenue figures will set this in clear motion.. still a strong buy in my books...

View attachment 2157616

Expand

Like I said, that 20c was always a very huge barrier, Coviu and Phenix announcement of official launching ResAppDx is needed to break it.....

RAP Price at posting: 17.5¢ Sentiment: Buy Disclosure: Held
2 Upvote

0 Great analysis

Reply

Top Stories

Trump is President Again: What Does This Mean for Crypto?

NHF

Burgeoning NZ insurance claims drive 1H25 operating loss for nib

MKT

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

3DA

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

ACW

Actinogen receives $9M R&D tax rebate to fund Alzheimer's trial